Accessibility Menu
Cryosite logo

Cryosite(ASX) CTE

Market CapA$61.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2002)+405%
5 Year+244%
1 Year+45%
1 Month+4%
A$1.25
+0.00%
+0.00Today
Cryosite last closing stock price
MetricPriceDate
Last closeAUD 1.252026-09-07
Cryosite stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 1.252026-08-25
1 month+4.17%AUD 1.202026-07-21
3 month+17.92%AUD 1.062026-06-04
Year to date+25%AUD 1.002025-12-29
1 year+45.35%AUD 0.862025-09-04
3 year+117.96%AUD 0.572023-09-05
5 year+244.27%AUD 0.362021-09-08
Since inception+404.98%AUD 0.252002-05-09

Cryosite Financials at a Glance

Market Cap

A$61.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$30.82M

Net Income (TTM)

A$4.12M

EPS (TTM)

A$0.04

P/E Ratio

27.29

Dividend

A$0.00

Beta (Volatility)

0.00 (Low)

Price

A$1.25

Volume

0

Open

A$1.25

Previous Close

A$1.25

Daily Range

A$1.25 - A$1.25

52-Week Range

A$0.80 - A$1.40

Estimated Earnings Date

Feb 18, 2026

CTE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cryosite

Cryosite Limited is a specialized provider of logistics and storage solutions for the life sciences industry in Australia. Established in 1999, the company operates through two main divisions: Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage.

Products and Services
  • Temperature-controlled storage for biological samples
  • Comprehensive logistics support for clinical trials
  • Cryogenic preservation of cord blood and tissue samples
Growth Outlook
  • Recent quarterly revenue reached AUD 8.43 million, indicating strong demand
  • Gross profit margin improved to 57.66% in the latest quarter
  • Operating income increased to AUD 1.58 million, reflecting operational efficiency
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 31.5 million, showcasing consistent growth
  • Net income margin of 13.38% demonstrates profitability
  • Current ratio of 1.12 indicates solid short-term financial health
Cryosite Limited has established itself as a key player in the life sciences logistics sector, providing essential services that support clinical research and the preservation of biological materials. The company's recent financial performance highlights its ability to generate revenue and maintain profitability, making it an attractive option for potential investors. With a focus on operational efficiency and a growing client base, Cryosite is well-positioned for future growth in the expanding healthcare market.
AI Generated • Sep 5, 2026

Industry

Life Sciences Tools and Services

Employees

27

CEO

John Hogg

Headquarters

South Granville, NSW 2142, AU

CTE Financials

Key Financial Metrics (TTM)

Gross Margin

56.96%

Operating Margin

18.92%

Net Income Margin

13.38%

Return on Equity

52.84%

Return on Capital

25.14%

Return on Assets

8.61%

Earnings Yield

3.66%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$61.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

48.81M

Volume

0

Avg. Volume

2.09K

Financials (TTM)

Gross Profit

A$18.40M

Operating Income

A$5.66M

EBITDA

A$7.40M

Operating Cash Flow

A$4.79M

Capital Expenditure

-A$11.45M

Free Cash Flow

-A$6.66M

Cash & ST Invst.

A$2.24M

Total Debt

A$7.72M

Cryosite Performance Analysis

Cryosite annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 11,935,0001.5%
20242024-06-30AUD 12,612,0005.7%
20252025-06-30AUD 14,116,00011.9%
20262026-06-30AUD 16,700,00018.3%
Cryosite sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-316.9%
Q42025-06-3012.6%
Q22025-12-3110.7%
Q42026-06-301.9%
Cryosite annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD 0.033.6%
20242024-06-30AUD 0.0430.4%
20252025-06-30AUD 0.040.3%
20262026-06-30AUD 0.0414.8%
Cryosite sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-15.7%
Q42025-06-3020.3%
Q22025-12-318.2%
Q42026-06-30-6.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$8.43M

+35.7%

Gross Profit

A$4.86M

+33.4%

Gross Margin

57.66%

N/A

Market Cap

A$61.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.26M

N/A

Employees

27

N/A

Net Income

A$1.10M

+10.4%

EBITDA

A$2.06M

+28.7%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$2.24M

-52.3%

Total Debt

A$7.72M

+215.7%

Accounts Receivable

A$2.57M

+82.6%

Inventory

A$57.00K

-3.4%

Long Term Debt

A$7.50M

+230.9%

Short Term Debt

A$220.00K

+22.9%

Return on Assets

8.61%

N/A

Return on Invested Capital

14.83%

N/A

Free Cash Flow

-A$5.79M

-523.8%

Operating Cash Flow

A$1.43M

-12.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NUZ.AXNeurizon Therapeutics Limited
A$0.06-1.59%
CMP.AXCompumedics Limited
A$0.24-4.00%
MAP.AXMicroba Life Sciences Limited
A$0.06+2.70%
IIQ.AXINOVIQ Ltd
A$0.18+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About CTE

What is the current price of Cryosite?

Cryosite is trading at A$1.25 per share.

What is the 52-week range for Cryosite?

Over the past 52 weeks, Cryosite has traded between A$0.80 and A$1.40.

How much debt does Cryosite have?

As of the most recent reporting period, Cryosite reported total debt of A$7.72M.

How much cash does Cryosite have on hand?

Cryosite reported A$2.24M in cash and cash equivalents in its most recent financial results.

What is Cryosite’s dividend yield?

Cryosite does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.